Want to see PBH full AI Analyst Report?
Prestige Consumer Healthcare (PBH) AI Stock Analysis
Prestige Consumer Healthcare
(NYSE:PBH)
The score is driven primarily by strong financial performance (profitability and robust free cash flow) and a supportive earnings outlook with raised acquisition-driven guidance. Technicals are constructive but show signs of being stretched short term (high Stochastic). Valuation appears reasonable on P/E, though no dividend yield data is provided.
Prestige Consumer Healthcare (PBH) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.32B
- Dividend Yield
- ―
- Average Volume (3M)
- 563.43K
- Price to Earnings (P/E)
- 13.7
- Beta (1Y)
- 0.39
- Revenue Growth
- -1.36%
- EPS Growth
- -16.45%
- Country
- US
- Employees
- 890
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
Prestige Consumer Healthcare Business Overview & Revenue Model
Company Description
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's...
How the Company Makes Money
Prestige Consumer Healthcare primarily makes money by selling branded OTC consumer healthcare products to retailers and distributors, recognizing revenue when control of products transfers under its customer arrangements. Its key revenue streams are...
Prestige Consumer Healthcare Earnings Call Summary
The call communicated a broadly positive operational and financial start to fiscal '27: reported revenue and adjusted EBITDA grew, record adjusted free cash flow was delivered, and two strategic acquisitions (Breathe Right and LaCorium) were closed and are expected to meaningfully expand revenue and margins. Management acknowledged notable near-term challenges — most prominently Clear Eyes supply variability from Pillar5 integration, YoY gross margin pressure from transportation costs, international distributor timing, and elevated debt/interest costs — but provided specific remediation and integration plans, maintained organic growth guidance (1%–3%) and raised reported guidance driven by acquisitions. Given the strong cash flow, completed integration of Breathe Right, accretive acquisition profile, and maintained outlook despite manageable headwinds, the overall tone and expected trajectory are positive.
Q1-2027 Updates
Positive Updates
Negative Updates
Company Guidance
Prestige updated fiscal 2027 guidance calling for revenues of $1.29–$1.315 billion (organic growth 1–3%), driven by the Breathe Right and LaCorium acquisitions which are expected to contribute roughly $190 million this year (Breathe Right ~ $200M annualized; LaCorium ~ $40M) and add more than 20% to annualized revenue; Q2 revenue is guided to $328–$331 million. Full‑year adjusted diluted EPS is $4.55–$4.65 (Q2 EPS ~$1.06–$1.08); adjusted gross margin is expected to be just over 57% for Q2 and the full year (Q1 was ~55%, down 120 bps YoY); A&M spend is guided to ~14.5% of sales for Q2/FY (Q1 A&M was $34.7M or 13%); adjusted G&A ~10% of sales for the year (Q1: 11.5%). The company expects at least $270 million of adjusted free cash flow in fiscal ’27 (Q1 record FCF $83.7M), a year‑end leverage ratio just below 4x (net debt ~$2.0B at June 30), and flagged higher interest and amortization in the back half of the year of roughly $100M and $33M respectively, while noting steps to extend maturities (earliest now 2031), issue $400M of new notes and prioritize debt paydown.
Prestige Consumer Healthcare Financial Statement Overview
Summary
Strong profitability and cash generation are the key strengths (healthy margins; robust operating cash flow and free cash flow with good cash conversion). Balance sheet leverage has improved but remains meaningful, and the 2023 earnings disruption highlights volatility risk despite the subsequent rebound.
Income Statement
78PositiveBalance Sheet
74PositiveCash Flow
82Very Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.10B | 1.09B | 1.14B | 1.13B | 1.13B | 1.09B |
| Gross Profit | 588.49M | 574.64M | 634.46M | 624.45M | 625.29M | 620.65M |
| EBITDA | 312.70M | 331.11M | 361.99M | 373.86M | 7.87M | 358.84M |
| Net Income | 172.01M | 190.30M | 214.60M | 209.34M | -82.31M | 205.38M |
Balance Sheet | ||||||
| Total Assets | 4.57B | 3.55B | 3.40B | 3.32B | 3.35B | 3.67B |
| Cash, Cash Equivalents and Short-Term Investments | 89.13M | 63.87M | 97.88M | 46.47M | 58.49M | 27.18M |
| Total Debt | 2.06B | 1.05B | 1.04B | 1.14B | 1.37B | 1.51B |
| Total Liabilities | 2.65B | 1.66B | 1.57B | 1.66B | 1.91B | 2.09B |
| Stockholders Equity | 1.92B | 1.89B | 1.83B | 1.66B | 1.45B | 1.58B |
Cash Flow | ||||||
| Free Cash Flow | 235.36M | 246.45M | 243.29M | 239.38M | 221.93M | 250.28M |
| Operating Cash Flow | 249.40M | 257.63M | 251.51M | 248.93M | 229.72M | 259.92M |
| Investing Cash Flow | -1.20B | -136.84M | -17.45M | -20.11M | -11.58M | -256.51M |
| Financing Cash Flow | 898.67M | -156.06M | -182.07M | -241.01M | -185.85M | -7.57M |
Prestige Consumer Healthcare Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBH, the sentiment is Positive. The current price of 49.53 is above the 20-day moving average (MA) of 48.31, above the 50-day MA of 48.53, and below the 200-day MA of 54.09, indicating a neutral trend. The MACD of 0.14 indicates Negative momentum. The RSI at 54.14 is Neutral, neither overbought nor oversold. The STOCH value of 51.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PBH.
Prestige Consumer Healthcare Risk Analysis
Prestige Consumer Healthcare disclosed 25 risk factors in its most recent earnings report. Prestige Consumer Healthcare reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksPrestige Consumer Healthcare Peers Comparison
Overall Rating
- PBH76.9Outperform
BFRI49Neutral
SCYX47Neutral
COSM41Neutral
NSRX28Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| PBH | 77Outperform | $2.32B | 13.66 | 9.22% | ― | -1.36% | -16.45% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| BFRI | 49Neutral | $12.96M | -1.45 | -127.78% | ― | 17.83% | 73.13% |
| SCYX | 47Neutral | $37.51M | -2.05 | -21.10% | ― | 489.78% | 45.39% |
| COSM | 41Neutral | $30.99M | -0.47 | -118.89% | ― | 33.82% | 34.05% |
| NSRX | 28Underperform | $35.95M | -2.99 | -158.83% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PBH | Prestige Consumer Healthcare | 49.06 | -11.52 | -19.02% | |
| SCYX | SCYNEXIS Inc | 3.77 | -1.34 | -26.21% | |
| COSM | Cosmos Holdings | 0.31 | -0.47 | -60.39% | |
| BFRI | Biofrontera, Inc. | 0.87 | -0.23 | -20.73% | |
| NSRX | Nasus Pharma Ltd. | 3.07 | -4.54 | -59.66% | |
| CUVL | Clinuvel Pharmaceuticals Limited Sponsored ADR | 5.07 | -2.28 | -31.01% |
Prestige Consumer Healthcare Corporate Events
Prestige Consumer Healthcare Announces Operations Leadership Transition
NeutralOn August 10, 2026, Prestige Consumer Healthcare Inc. announced that Jeffrey Zerillo had informed the company of his decision to retire from his role as Senior Vice President, Operations. His retirement from this position and all other roles at the c...
Prestige Consumer Healthcare Lifts Outlook on Acquisition-Driven Growth
PositivePrestige Consumer Healthcare reported that first-quarter fiscal 2027 revenue for the period ended June 30, 2026 rose 6.5% year on year to $265.7 million, with organic sales up 3.2%, driven by broad-based strength in gastrointestinal, dermatological a...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 06, 2026